A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...

NEW YORK, NY / ACCESS Newswire / January 27, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

A Novo Nordisk A/S investor says the pharmaceutical company’s failure to disclose how it tested experimental obesity shot ...

The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Novo Nordisk A/S securities between November 2, 2022 and December 19, 2024, both dates inclusive (the "Class ...

On Friday, the Danish pharma giant released the stellar results from a phase 1/2 trial for a once-weekly jab in its pipeline.

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Novo Nordisk A/S securities between November 2, 2022 and December 19, 2024 ...

Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...

On Friday, however, Novo Nordisk announced top-line results in yet another trial. While the results don't initially sound as ...